Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.

Androgen Receptor Antagonists / therapeutic use Cell-Free Nucleic Acids Humans Male Prognosis Prospective Studies Prostatic Neoplasms, Castration-Resistant / pathology Receptors, Androgen / genetics
Abiraterone Androgen receptor pathway inhibitor Biomarker Castrate resistant Cell-free DNA Enzalutamide Liquid biopsy Prostate cancer

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
11 2021
Historique:
received: 14 04 2020
revised: 28 06 2020
accepted: 08 07 2020
pubmed: 3 8 2020
medline: 14 4 2022
entrez: 3 8 2020
Statut: ppublish

Résumé

Total plasma cell-free DNA (cfDNA) levels were recently shown to be prognostic in two large phase III trials of taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). However, whether cfDNA concentration is predictive of treatment outcomes with androgen receptor pathway inhibitors (ARPIs) is unknown. We quantified plasma cfDNA levels at baseline (n = 74) and 4 weeks on treatment (n = 56) in a prospective cohort of mCRPC patients treated with the ARPIs abiraterone acetate or enzalutamide. Elevated total cfDNA concentration (log

Identifiants

DOI: 10.1016/j.euf.2020.07.001 PMID: 32739405
pubmed: 32739405
pii: S2405-4569(20)30207-8
doi: 10.1016/j.euf.2020.07.001
pii:
doi:

Substances chimiques

Androgen Receptor Antagonists 0
Cell-Free Nucleic Acids 0
Receptors, Androgen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1287-1291

Informations de copyright

Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Heidi Fettke (H)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.

Edmond M Kwan (EM)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia; Department of Medical Oncology, Monash Health, Clayton, VIC, Australia.

Patricia Bukczynska (P)

Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Nicole Ng (N)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.

Tu Nguyen-Dumont (T)

Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.

Melissa C Southey (MC)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.

Ian D Davis (ID)

Medical Oncology Unit, Eastern Health, Box Hill, VIC, Australia; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.

Andrew Mant (A)

Medical Oncology Unit, Eastern Health, Box Hill, VIC, Australia; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.

Phillip Parente (P)

Medical Oncology Unit, Eastern Health, Box Hill, VIC, Australia; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.

Carmel Pezaro (C)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England.

Christine Hauser (C)

Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Arun A Azad (AA)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: arun.azad@petermac.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Antihormones › Antagonistes des androgènes › Antagonistes du récepteur des androgènes › Prognostic Impact of Total Plasma Cell-free...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › Acides nucléiques acellulaires › Prognostic Impact of Total Plasma Cell-free...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prognostic Impact of Total Plasma Cell-free...
questionsmedicales.fr › Diagnostic › Pronostic › Prognostic Impact of Total Plasma Cell-free...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Prognostic Impact of Total Plasma Cell-free...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Prognostic Impact of Total Plasma Cell-free...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs aux androgènes › Prognostic Impact of Total Plasma Cell-free...